The Prophylactic HIV Drugs Market is expected to expand from US$261.82 million in 2025 to US$383.79 million by 2034, registering a CAGR of 4.90% from 2026 to 2034. Market growth is being supported by increasing awareness of HIV prevention, broader access to preventive therapies, public health initiatives, and continued pharmaceutical innovation. The expansion of...